Vitura Health Ltd 2025 AR2
The report outlines Vitura Health Limited's financial and operational performance for the 2025 fiscal year, highlighting the execution of its Strategy Reset. The company achieved a 23.5% increase in EBITDA to $7.6 million and declared its third fully franked dividend, despite industry-wide margin compression. Key strategic milestones included the acquisition of Candor Medical, securing full ownership of the Canview platform, and expanding its clinic network through the Flora joint venture. Additionally, Vitura expanded its presence in the therapeutic nicotine vaping and psychedelic medicine markets.
Company: Vitura Health Ltd
Sector: Health Care
Country: Australia
Year: 2025
Type: AR2
Pages: 126
Vitura Health Ltd
Annual Report
The report outlines Vitura Health Limited's financial and operational performance for the 2025 fiscal year, highlighting the execution of its Strategy Reset. The company achieved a 23.5% increase in EBITDA to $7.6 million and declared its third fully franked dividend, despite industry-wide margin compression. Key strategic milestones included the acquisition of Candor Medical, securing full ownership of the Canview platform, and expanding its clinic network through the Flora joint venture. Additionally, Vitura expanded its presence in the therapeutic nicotine vaping and psychedelic medicine markets.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jul 1, 2024 - Jun 30, 2025
Fiscal Year
2025
Published
Oct 22, 2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees